Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) Antikörper

Antigen: Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A)

Synonyme: EPM2, MELF

Klonalität: Monoklonal (K2A3)

Wirt: Maus

Reaktivität: Human

Applikation: ELISA, Western Blot (WB)

Produktnummer: ABIN361048

Produktbeschreibung

Weitere Bezeichnung: EPM2A

Immunogen: Recombinant human EPM2A (243-331aa), Accession / GI number: NP_005661

Isotyp: IgG1, kappa chain  (Passende Sekundärantikörper)

Klon: K2A3

Beschreibung: Epilepsy, progressive myoclonus type 2A (EPM2A), also known as laforin, is a dual-specificity phosphatase that associates with polyribosomes. The protein may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules. Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2(EPM2), also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy. Synonyms: Laforin isoform a

Anwendungen

Applikationshinweise: Recommended dilution 1:1000

Konzentration: 1mg/ml

Reinigung: The antibody was purified from mouse ascitic fluids by protein-G affinity chromatography

Buffer: In Phosphate-Buffered Saline (pH7.4) with 0.1% Sodium Azide

Lagerung: Store at -20°, Aliquot to avoid repeated freezing and thawing.

Forschungsgebiet: Enzyme

Beschränkungen: Nur für Forschungszwecke einsetzbar

Bilder

anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) antibody